TY - JOUR
KW - adherence
KW - diabetes mellitus
KW - type 2
KW - weight change
AU - T. Weiss
AU - L. Yang
AU - R. Carr
AU - S. Pal
AU - B. Sawhney
AU - R. Boggs
AU - S. Rajpathak
AU - K. Iglay
AD - Merck & Co., Inc, Kenilworth, New Jersey, USA tracey.weiss@merck.com.
Merck & Co., Inc, Kenilworth, New Jersey, USA.
University College London, London, UK.
Complete HEOR Solutions, North Wales, Pennsylvania, USA.
AN - 35101924
BT - BMJ Open Diabetes Res Care
DO - 10.1136/bmjdrc-2021-002517
DP - NLM
ET - 2022/02/02
LA - eng
M1 - 1
N1 - 2052-4897
Weiss, Tracey
Orcid: 0000-0001-6524-2412
Yang, Lingfeng
Carr, Richard D
Pal, Sampriti
Sawhney, Baanie
Boggs, Robert
Rajpathak, Swapnil
Orcid: 0000-0002-6052-2949
Iglay, Kristy
Journal Article
England
BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002517. doi: 10.1136/bmjdrc-2021-002517.
PY - 2022
SN - 2052-4897
T2 - BMJ Open Diabetes Res Care
TI - Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
VL - 10
ER -